Listar por tema "Neoplasm Recurrence, Local/drug therapy"

Mostrando ítems 1-4 de 4

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

Manzano, José-Luis; Martín-Liberal, Juan; Fernández-Morales, Luis-A; Benítez, Gretel; Medina-Martínez, Javier; Quindos, María; García-Castaño, Almudena; Fernández, Ovidio; Simo, Rocío-V; Majem, Margarita; Bellido, Lorena; Ayala-de-Miguel, Pablo; Campos, Begoña; Espinosa, (LIPPINCOTT WILLIAMS & WILKINS, 2023-10)

BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF-V600 mutations. However, real-world evidence is limited. We aimed to determine the ...
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Tilmont, Remi; Yakoub-Agha, Ibrahim; Eikema, Diderik-Jan; Zinger, Nienke; Haenel, Mathias; Schaap, Nicolaas; Herrera-Arroyo, Concepción; Schuermans, Christine; Besemer, Britta; Engelhardt, Monika; Kuball, Jurgen; Michieli, Maríagrazia; Schub, Natalie; Wilson, Keith-MO; Bourhis, Jean-Henri; Mateos, María-Victoria; Rabin, Neil; Jost, Edgar; Kroeger, Nicolaus; Moraleda-Jiménez, José-María; Za, Tommaso; Hayden, Patrick-J; Beksac, Meral; Mclornan, Donal; Schoenland, Stefan; Manier, Salomon (SPRINGERNATURE, 2023-11)

In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this ...
Long-term follow-up of ef fi cacy and safety of selinexor maintenance treatment in patients with TP53 wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Makker, Vicky; Pérez-Fidalgo, José-Alejandro; Valabrega, Giorgio; Hamilton, Erika; Van-Gorp, Toon; Sehouli, Jalid; Reginacova, Klaudia; Richardson, Debra-L; Perri, Tamar; Oza, Amit-M; Miller, David-S; Guerra-Alia, Eva-María; de-Giorgi, Ugo; Henry, Stephanie; Spitz, Daniel-L; Wimberger, Pauline; Bednarikova, Marketa; Chon, Hye-Sook; Martínez-García, Jerónimo; Pisano, Carmela; Berek, Jonathan-S; Romero, Ignacio; Scambia, Giovanni; Farinas-Madrid, Lorena; Buscema, Joseph; Schochter, Fabienne; Li, Kai; Kalyanapu, Pratheek; Walker, Christopher-J; Vergote, Ignace (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2024-06)

OBJECTIVE: To report long-term efficacy and safety of selinexor maintenance therapy in adults with TP53 wild-type (TP53wt) stage IV or recurrent endometrial cancer (EC) who achieved partial remission (PR) or complete ...
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

Rubio, María-Jesus; Manzano, Aranzazu; de-Sande, Luis-Miguel; Estevez-García, Purificación; Gordon, María-del-Mar; Soto-de-Prado, Diego; Hernando-Fernández-de-Aranguiz, Blanca; Guerra-Alia, Eva-María; Carbo-Bague, Anna; Romero, Ignacio; Corbellas, Miguel; González-Haba, Alba; Robles-Barraza, Carlos-E; Martínez-García, Jerónimo; González-Martín, Antonio (BMC, 2024-07)

BACKGROUND: Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients with platinum-sensitive relapsed ovarian cancer. Nevertheless, there is currently limited information ...

Mostrando ítems 1-4 de 4

Buscar en DSpace

Búsqueda avanzada

Listar

Todo RICSMUR

Listar por tema "Neoplasm Recurrence, Local/drug therapy"

Listar por tema "Neoplasm Recurrence, Local/drug therapy"

Buscar en DSpace

Listar

Todo RICSMUR

Mi cuenta